Recruiting

Mia Self-Collection

Sponsor:

Mel Mont Medical

Code:

NCT07758140

Conditions

HPV

HPV - Anogenital Human Papilloma Virus Infection

Eligibility Criteria

Sex: Female

Age: 25 - 65

Healthy Volunteers: Accepted

Interventions

Mia by XytoTest

Rovers Cervex-Brush

Study Details

Brief summary:

To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening.

To assess the clinical performance of Mia self-collected vaginal specimens by evaluating agreement with paired clinician-collected cervical specimens for the detection of high-risk HPV, when both specimen types are analyzed using the cobas HPV Test (Roche Molecular Systems). Residual samples may be used to determine adequacy for additional assays that require vaginal and/or cervical specimens (such as mRNA E6 and E7 Biomarker Test, dual stain cytology).

Conditions

HPV

HPV - Anogenital Human Papilloma Virus Infection

Study ID

NCT07758140

Start date

Jul 9, 2026

Status verified date

Aug, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 25 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

Group 1: General Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.

Group 2: Enriched Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.
3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.

Exclusion Criteria:

Apply to all groups:

1. Impaired decision-making capacity or inability to provide informed consent.
2. History of partial or total hysterectomy, including removal of the cervix.
3. Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy).
4. Current pregnancy (based on self-reporting).
5. Active menstruation at time of specimen collection.
6. Vaginal bleeding within 48 hours.
7. Have had sex or used tampons, creams, or other vaginal products in the last 48 hours.
8. Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study.
9. Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.

Study Design

Enrollment

260 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Screening

Interventions and Outcome Measures

Arms

active comparator: General Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.

active comparator: Enriched Population Group

1. Participants are 25 to 65 years of age and willing to provide informed consent.
2. Participants have an intact cervix.
3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.

Interventions

Mia by XytoTest

Mia by XytoTest is a single-use, sterile, disposable device intended for self-collection of vaginal specimens

Rovers Cervex-Brush

Rovers Cervex-Brush is for physician collection of vaginal specimens.

Primary outcome measure

  • Rate of SAEs [ Time Frame: Between 6 and 14 days. ]
  • NPA and PPA [ Time Frame: Within one week of sample collection. ]

Central Contacts and Locations

Locations

ASR Arizona CGA

Recruiting

Phoenix, Arizona, United States, 85004

Contacts

Integrated Clinical Research

Recruiting

Sherman Oaks, California, United States, 91403

Contacts

Altus Clinical Research

Recruiting

Lake Worth, Florida, United States, 33461

Contacts

Zenacare Research

Recruiting

North Miami Beach, Florida, United States, 33169

Contacts

ASR Idaho CGI

Recruiting

Boise, Idaho, United States, 83702

Contacts

Boeson Research - Great Falls

Recruiting

Great Falls, Montana, United States, 59405

Contacts

Unified Women's Clinical Research

Recruiting

Raleigh, North Carolina, United States, 27607

Contacts

Innovo-Wilmington Health

Recruiting

Wilmington, North Carolina, United States, 28401

Contacts

Lyndhurst Clinical Research (Unified)

Recruiting

Winston-Salem, North Carolina, United States, 27103

Contacts

Amie Butler

336-765-9350

El Centro de Corazon

Recruiting

Houston, Texas, United States, 77012

Contacts

National Eagle Research

Recruiting

Lynnwood, Washington, United States, 98036

Contacts

More Information

Sponsor

Mel Mont Medical

Last update posted

Aug 11, 2026

Last verified

Aug, 2026

Keywords

  • hrHPV
  • cobas HPV test

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-03. This information was provided to ClinicalTrials.gov by Mel Mont Medical on 2026-08-11.